欧盟将于12月6日前对诺和诺德作出裁决

智通财经11-04

智通财经APP获悉，根据欧盟委员会网站周一发布的文件，欧盟反垄断监管机构将在12月6日之前决定是否批准诺和诺德(NVO.US)收购美国合同制药商Catalent(CTLT.US)。文件显示，诺和诺德控股股东于10月31日向欧盟提交了批准该交易的请求。欧盟反垄断监管机构可以在有或没有补救措施的情况下批准这笔交易，也可以在有严重担忧的情况下展开为期4个月的全面调查。此次收购于今年2月宣布，突显了丹麦...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2480798573?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-04 16:57","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2480798573","market":"us","top_or_hot":-1,"title":"欧盟将于12月6日前对诺和诺德作出裁决","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，根据欧盟委员会网站周一发布的文件，欧盟反垄断监管机构将在12月6日之前决定是否批准诺和诺德(NVO.US)收购美国合同制药商Catalent(CTLT.US)。文件显示，诺和诺德控股股东于10月31日向欧盟提交了批准该交易的请求。欧盟反垄断监管机构可以在有或没有补救措施的情况下批准这笔交易，也可以在有严重担忧的情况下展开为期4个月的全面调查。此次收购于今年2月宣布，突显了丹麦...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104170309ab9de4d8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>欧盟将于12月6日前对诺和诺德作出裁决</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n欧盟将于12月6日前对诺和诺德作出裁决\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 16:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104170309ab9de4d8&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，根据欧盟委员会网站周一发布的文件，欧盟反垄断监管机构将在12月6日之前决定是否批准诺和诺德(NVO.US)收购美国合同制药商Catalent(CTLT.US)。文件显示，诺和诺德控股股东于10月31日向欧盟提交了批准该交易的请求。欧盟反垄断监管机构可以在有或没有补救措施的情况下批准这笔交易，也可以在有严重担忧的情况下展开为期4个月的全面调查。此次收购于今年2月宣布，突显了丹麦...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104170309ab9de4d8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104170309ab9de4d8&s=b","article_id":"2480798573","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104170309ab9de4d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2480798573","pubTimestamp":1730710637,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"智通财经APP获悉，根据欧盟委员会网站周一发布的文件，欧盟反垄断监管机构将在12月6日之前决定是否批准诺和诺德收购美国合同制药商Catalent。文件显示，诺和诺德控股股东于10月31日向欧盟提交了批准该交易的请求。欧盟反垄断监管机构可以在有或没有补救措施的情况下批准这笔交易，也可以在有严重担忧的情况下展开为期4个月的全面调查。此次收购于今年2月宣布，突显了丹麦制药商诺和诺德提高其畅销减肥药Wegovy产量的努力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4532":"文艺复兴科技持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","CTLT":"Catalent","LLY":"礼来","BK4530":"医药外包概念","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","BK4007":"制药","NVO":"诺和诺德"},"translate_title":"EU to rule on Novo Nordisk by December 6","themeId":"c8930b257377b3ad681bfe33e024f8d5","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"CTLT":0.9,"LLY":0.7},"content_text":"智通财经APP获悉，根据欧盟委员会网站周一发布的文件，欧盟反垄断监管机构将在12月6日之前决定是否批准诺和诺德(NVO.US)收购美国合同制药商Catalent(CTLT.US)。文件显示，诺和诺德控股股东于10月31日向欧盟提交了批准该交易的请求。欧盟反垄断监管机构可以在有或没有补救措施的情况下批准这笔交易，也可以在有严重担忧的情况下展开为期4个月的全面调查。此次收购于今年2月宣布，突显了丹麦制药商诺和诺德提高其畅销减肥药Wegovy产量的努力。诺和诺德和Catalent最近都重申了它们的预期，即交易将在今年年底前完成。制药巨头罗氏呼吁执法者否决该交易，担心这笔交易可能会打击蓬勃发展的减肥药行业的竞争。诺和诺德在肥胖和糖尿病药物市场的主要竞争对手礼来(LLY.US)也表达了担忧。这笔交易也受到了美国消费者团体的批评，他们上个月敦促美国联邦贸易委员会阻止该交易，称其威胁到减肥药物行业的竞争。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480798573"}